Standard
Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2. / Israelsen, Simone Bastrup; Pottegård, Anton; Sandholdt, Håkon; Madsbad, Sten; Thomsen, Reimar Wernich; Benfield, Thomas.
I:
Diabetes, Obesity and Metabolism, Bind 23, Nr. 6, 01.06.2021, s. 1397-1401.
Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt
Harvard
Israelsen, SB, Pottegård, A, Sandholdt, H
, Madsbad, S, Thomsen, RW
& Benfield, T 2021, '
Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2',
Diabetes, Obesity and Metabolism, bind 23, nr. 6, s. 1397-1401.
https://doi.org/10.1111/dom.14329APA
Israelsen, S. B., Pottegård, A., Sandholdt, H.
, Madsbad, S., Thomsen, R. W.
, & Benfield, T. (2021).
Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2.
Diabetes, Obesity and Metabolism,
23(6), 1397-1401.
https://doi.org/10.1111/dom.14329Vancouver
Israelsen SB, Pottegård A, Sandholdt H
, Madsbad S, Thomsen RW
, Benfield T.
Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2.
Diabetes, Obesity and Metabolism. 2021 jun. 1;23(6):1397-1401.
https://doi.org/10.1111/dom.14329Author
Israelsen, Simone Bastrup ; Pottegård, Anton ; Sandholdt, Håkon ; Madsbad, Sten ; Thomsen, Reimar Wernich ; Benfield, Thomas. / Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2. I: Diabetes, Obesity and Metabolism. 2021 ; Bind 23, Nr. 6. s. 1397-1401.
Bibtex
@article{a48f65d7abd24fe89c04204803d9b62a,
title = "Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2",
author = "Israelsen, {Simone Bastrup} and Anton Potteg{\aa}rd and H{\aa}kon Sandholdt and Sten Madsbad and Thomsen, {Reimar Wernich} and Thomas Benfield",
year = "2021",
month = jun,
day = "1",
doi = "10.1111/dom.14329",
language = "English",
volume = "23",
pages = "1397--1401",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "6",
}
RIS
TY - JOUR
T1 - Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2
AU - Israelsen, Simone Bastrup
AU - Pottegård, Anton
AU - Sandholdt, Håkon
AU - Madsbad, Sten
AU - Thomsen, Reimar Wernich
AU - Benfield, Thomas
PY - 2021/6/1
Y1 - 2021/6/1
U2 - 10.1111/dom.14329
DO - 10.1111/dom.14329
M3 - Letter
C2 - 33502076
VL - 23
SP - 1397
EP - 1401
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
SN - 1462-8902
IS - 6
ER -
